Hypera S.A., traded on B3 under the ticker HYPE3, is a publicly held company headquartered in São Paulo whose trajectory began in 2001, when the then Monte Cristalina acquired Prátika Industrial, owner of the Assolan brand in the hygiene and cleaning segment. Throughout the 2000s, the company went through a period of diversification in consumer goods, operating in cosmetics, personal care products, food, cleaning products, disposables and condoms, through brands such as Monange, Risqué, Etti, Salsaretti, Assim, Pom Pom and Olla, among others. Starting in 2011, it initiated a portfolio rotation movement, gradually divesting from these businesses. Between 2011 and 2017, it sold food, cleaning, cosmetics, disposables and condom operations to groups such as Bunge, Flora, Química Amparo, Coty, Ontex and Reckitt Benckiser, progressively focusing on the pharmaceutical market. In 2018, the change of corporate name to Hypera S.A. was accompanied by the adoption of the corporate brand “Hypera Pharma,” reflecting its exclusive focus on the healthcare sector. In 2023, the company was included in the B3 Corporate Sustainability Index (ISE) portfolio, reinforcing its visibility in the Brazilian capital market.

The transformation of Hypera into a predominantly pharmaceutical company was built through an extensive cycle of acquisitions and industrial reorganization. Entry into the sector occurred in 2007 with the acquisition of DM Indústria Farmacêutica, then the national vice-leader in over-the-counter (OTC) medicines and owner of brands such as Benegrip, Doril, Engov, Epocler, Biotônico Fontoura, Lacto-Purga and Merthiolate. In 2008, the purchase of Laboratório Americano de Farmacoterapia (Farmasa) consolidated its leadership in OTC and marked its entry into prescription medicines, expanding its relationship with the medical community through brands such as PredSim, Milgamma and Lipanon. In 2009, the acquisition of Neo Química significantly expanded its presence in similar and generic medicines, turning this brand into one of the leaders in the segment in Brazil. Additional moves, such as the acquisition of Luper Indústria Farmacêutica in 2010 and Mantecorp in 2011, complemented the portfolio with new prescription brands, dermocosmetics and OTC products, including Coristina D, Polaramine, Celestamine, Diprospan, Quadriderm and Episol.

Hypera’s current business model is structured around five major fronts: Prescription Products, Consumer Health, Similar and Generic Medicines, Skincare and the Institutional Market. The Prescription Products unit covers prescription medicines (RX), dermocosmetics prescribed by physicians and OTX medicines, which, although over the counter, have their demand driven by promotion to the medical community. In this segment, the company operates across several therapeutic classes, such as analgesics, anti-inflammatories, antidiabetics, antihypertensives, antidepressants and vitamins, with brands such as Alivium, Lisador, Maxsulid, Nesina, Persur, Evortia, Milgamma, Rinosoro, Dramin and Addera D3. The Consumer Health unit concentrates OTC medicines and the sweetener portfolio, with key brands including Benegrip, Coristina D, Neosaldina, Doril, Engov, Estomazil, Gastrol, Polaramine, Lacto-Purga, Tamarine, Maracugina, Buscopan, Buscofem, Merthiolate, Biotônico Fontoura and Vitasay. In sweeteners, Hypera operates brands such as Zero-Cal, Finn and Adocyl, with a broad presence in liquid and powdered versions.

The Similar and Generic Medicines unit, driven by the Neo Química brand, focuses on medicines that are interchangeable with reference products and sold at a discount to the official price list. The similar medicines line includes brands such as Doralgina, Corticorten, Neosoro, Flavonid, Neolefrin, Neotoss, Neopiridin, Vitaminas Neo Química, Neocoflan, Massageol, Histamin, Hiscongex, Miorrelax and Torsilax. In generics, the portfolio covers a wide range of active ingredients, such as acyclovir, alprazolam, amoxicillin, atenolol, atorvastatin, azithromycin, bromopride, captopril, sildenafil citrate, ciprofloxacin, sertraline, trazodone, dipyrone, zolpidem, losartan, enalapril, naproxen, olanzapine, tadalafil and vildagliptin, among others. The strategy of this unit combines volume, breadth of molecules and a competitive pricing policy, supported by bioequivalence tests and regulatory requirements from the Brazilian health authority to ensure interchangeability with reference medicines.

In the Skincare segment, Hypera operates mainly through the Mantecorp Skincare brand, focused on dermocosmetics developed for Brazilian skin, with lines for photoprotection, hydration, acne treatment, hyperpigmentation and specific care, such as Episol, Epidrat, Epidac, Pielus, Glycare, Blancy, Hidramamy and Lanidrat. Complementarily, it operates the Simple Organic brand, focused on organic and vegan products, and Bioage, targeted at professional treatments in aesthetic clinics. These products are guided by dermatological recommendations and are subjected to clinical studies to prove efficacy and safety. The Institutional Market focuses on supply to hospitals, clinics and the Public Health System, with a pipeline of new molecules and products, including biologics initiatives such as Hyblut, in addition to medicines such as Pabexhy and Hyfol, seeking to expand the company’s presence in hospital-use treatments.

Hypera’s operations are predominantly concentrated in the Brazilian pharmaceutical market, with commercial presence in 100% of the country’s states. Its industrial and logistics structure underwent consolidation between 2011 and 2014, with the transfer of its main pharmaceutical operations to Anápolis, in Goiás, one of the main industry hubs in Brazil. In this municipality, the company operates a distribution center with tens of thousands of storage positions, in facilities that meet Good Manufacturing Practices requirements and use integrated management systems (SAP). Pharmaceutical products and dermocosmetics are distributed mainly through the pharma channel, which includes large drugstore chains, specialized distributors and independent pharmacies. Sweeteners and some supplements are also sold through the food channel, encompassing supermarkets, hypermarkets, wholesalers and small retailers.

Hypera’s distribution chain combines direct sales to large retailers with an indirect channel based on distributors, which accounts for a relevant share of revenues from continuing operations. Transportation is primarily road-based and outsourced, using carriers specialized according to the sanitary and regulatory requirements applicable to the pharmaceutical sector. The sales force is segmented by business unit and includes in-house salespeople, promoters, demonstrators and outsourced representatives, focusing on in-store execution, shelf display, merchandising actions and trade marketing. In addition to interaction with retailers, the company maintains a structured relationship with the medical community, especially in the Prescription Products and Skincare units, which depend on professional recommendations.

From a regulatory standpoint, Hypera operates in a sector that is heavily supervised by health authorities, with strict requirements for registration, manufacturing, bioequivalence testing, pharmacovigilance and consumer communication. Generic and similar medicines must prove bioequivalence or bioavailability in relation to reference products, while OTC medicines and dermocosmetics follow specific rules for advertising and labeling. The company also participates in biotechnology initiatives such as the Bionovis joint venture, focused on biotechnological products, aligning itself with the trend toward the expansion of advanced therapies. In terms of environmental, social and governance practices, the presence of HYPE3 in B3’s Corporate Sustainability Index indicates the adoption of structured policies on corporate governance, socio-environmental responsibility and risk management, aspects that are increasingly monitored in the Brazilian stock market.

Sell-out figures by segment reinforce its profile as a diversified company within the pharmaceutical sector. In 2024, the Prescription Products, Consumer Health and Similar and Generic Medicines segments together accounted for most of the volume sold, while Skincare and the Institutional Market represented smaller but growing shares. This portfolio composition, based on widely recognized brands, multiple therapeutic categories and complementary distribution channels, positions Hypera as one of the leading pharmaceutical manufacturers listed on B3, focused on the Brazilian market for medicines, dermocosmetics and health and wellness products.